Skip to main content

Laboratory Corporation of America Holdings Value Stock - Dividend - Research Selection

Laboratory

ISIN: US50540R4092 , WKN: 895308

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women\'s health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?

2024-07-02
Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.

Labcorp to Announce Second Quarter Financial Results on August 1, 2024

2024-07-01
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Preeclampsia can be fatal for pregnant people and babies. New blood tests aim to show who's at risk

2024-06-24
When you're expecting a baby, you hope nothing goes wrong. But at least one in 20 people who are pregnant develop a scary complication called preeclampsia, a high blood pressure disorder that...

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Praxis Precision Medicines (PRAX) and Laboratory (LH)

2024-06-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Laboratory Corporation: Limited Upside Visibility, Reiterate Hold

2024-06-21
Labcorp's recent acquisition of assets from Invitae could add ~$275-300 million in annualized specialty testing revenue. Read why LH stock is a hold.

Interesting LH Put And Call Options For February 2025

2024-06-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Labcorp launches suite of laboratory solutions designed to expedite clinical trials

2024-06-18
The solutions aim to expedite the start of trials, maintain study momentum and increase trial throughput.

Ranking the top ten clinical research organisations in the world

2024-06-18
Clinical research organisations assist drug manufacturers during the clinical trial process to improve efficiency and speed. Igea Hub has created a ranking system for clinical research organisations primarily based on revenue ranging from Covance at number one with $10.441bn to Medpace at number ten with $436m.

Is Labcorp Holdings Inc. (NYSE:LH) Potentially Undervalued?

2024-06-17
Let's talk about the popular Labcorp Holdings Inc. ( NYSE:LH ). The company's shares saw significant share price...

Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

2024-06-17
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites.